Polyspecific antibodies for cancer research
AMSBIO announce a new range of high-quality bispecific antibodies (BsAbs) and trispecific antibodies (TsAbs) that can used to provide enhanced cancer therapeutic efficacy and/or safety compared to what can be achieved with conventional monospecific antibodies.
The concept of using a molecule with more than one binding site to enhance its biological function has been around for some time. Polyspecific antibodies are the basis of a new class of anti-cancer agents which offer the potential to be directed at multiple tumor antigens to eradicate tumor…
AMSBIO offer an extensive range of aptamers targeting many human proteins linked to cancer. Aptamers bind to target molecules with the same affinity and specificity as antibodies but offer significant advantages, in particular a lack of immunogenicity, which makes them an ideal tool for cancer diagnosis and therapy.
There are two major applications for aptamers in cancer therapy. Aptamers can be used as antagonists by targeting and inhibiting cancer-specific molecules. They can also be used as delivery vehicles for therapeutics by specifically targeting cell membrane receptors on cancer cells…
AMSBIO announce the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications.
Continued expansion of cell therapy applications across healthcare and the life sciences is driving a rapidly increasing need for clinically applicable ancillary materials. A key requirement is for recombinant proteins, such as growth factors and cytokines. This demand for clinically applicable recombinant proteins places stringent requirements on product quality, lot-to-lot consistency, and compliance with all relevant laws and regulations.
All StemFit…
AMSBIO is a leading supplier of high purity exosomes using isolation methods including traditional differential and gradient ultracentrifugation, immunoaffinity, size exclusion chromatography as well as precipitation / low speed centrifugation.
Exosomes are small endosome derived lipid nanoparticles actively secreted by exocytosis in most living cells. Release of exosomes occurs either constitutively or upon induction, under both normal and pathological conditions, in a dynamic, regulated and functionally relevant manner. Isolated from diverse cell lines, Exosomes have been shown to have…
In March 2021, the European Patent Office (EPO) Guidelines for Examination were updated to include a section devoted to the examination of antibody-related patent applications (Guidelines G-II, 5.6). This new section provided a much anticipated outline of the EPO requirements for different approaches to defining antibodies in patent claims (Guidelines G-II, 5.6.1) and helpful guidance in relation to the inventive step of antibodies in Europe (Guidelines G-II, 5.6.2). The new antibodies section of the EPO Guidelines was discussed in detail in our article “An antidote to antibody patent…
We have previously discussed the cell and gene therapy boom in the United Kingdom. The industry is thriving not only in the UK, but around the world, and here we take a quick look at some of the major successes and deals that have taken place in the last few months.
Gene therapy deals
As a quick reminder, gene therapy involves the transfer of genetic material, usually in a carrier or vector, into the appropriate cells for uptake of the genetic material. The vector can either be delivered outside the body (ex vivo treatment) where the targeted cells are removed from the patient and…
Cambridge, UK, 24 May 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks as Chief Business Officer. Key to the next stage of the Company’s growth, Paul will be responsible for shaping the company’s commercial business strategy and leading the expansion of its global commercial organisation.
Paul is an experienced C-suite level executive with over 25 years in the life science industry building businesses and leading high-performance research,…
Artificial Intelligence enters new phase of growth, as South Korea emerges as a key innovation frontrunner, new analysis from leading intellectual property firm, Marks & Clerk finds
- New analysis shows that whilst AI patent filings are still actively growing, the rate of this growth is slowing, a sign the market may now be maturing
- Number of EPO oppositions filed against patents rises again in 2021
- Computer vision technology sees growth in patent filings for fifth consecutive year
- Republic of Korea has the highest rate of AI applicants per capita
- The artificial intelligence (AI)…
A sample freezer failure is the worst case scenario for many laboratories. Do you have a process in place if your ULT freezer malfunctions?
It’s the worst case scenario for many laboratories and sample storage centres, your freezer has failed and your samples are ruined.
Whether it is due to the failure of a compressor, the power supply, or a temperature control issue, an ultra-low storage freezer failing can mean vital samples are spoiled within a matter of hours. With the sheer amount of user parts and variables in upright freezers it means that when they are employed for long term use,…
BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has chosen it to supply biosamples for the Neurofilament as a Blood-Based Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD) Project.
FTD, which…